Guideline on the Diagnosis and Treatment of Autoimmune bullous diseases -

Pemphigoid

Developed by the Guideline Subcommittee of the European Dermatology Forum

Subcommittee Members:
Prof. Dr. Claudio Feliciani, Parma (Italy)  Prof. Dr. Hana Jedlickova, Brno (Czech Republic)
Prof. Dr. Pascal Joly, Rouen (France)  Prof. Dr. Sarolta Karpati, Budapest (Hungary)
Prof. Dr. Marcel F. Jonkman, Groningen (Netherlands)  Prof. Dr. Branka Marinovic, Zagreb (Croatia)
Prof. Dr. Giovanna Zambruno, Roma (Italy)  Prof. Dr. Daniel Mimouni, Tel-Aviv (Israel)
Prof. Dr. Detlef Zillikens, Luebeck (Germany)  Prof. Dr. Soner Uzun, Antalya (Turkey)
Prof. Dr. Dimitrios Ioannides, Thessalonki (Greece)  Prof. Dr. Savas Yayli, Trabzon (Turkey)
Prof. Dr. Cezary Kowalewski, Warsaw (Poland)  Prof. Dr. Michael Hertl, Marburg (Germany)
Prof. Dr. Luca Borradori, Bern (Switzerland)

Members of EDF Guideline Committee:
Prof. Dr. Werner Aberer, Graz (Austria)  Prof. Dr. Dieter Metze, Muenster (Germany)
Prof. Dr. Martine Bagot, Paris (France)  Prof. Dr. Gillian Murphy, Dublin (Ireland)
PD Dr. Alexander Nast, Berlin (Germany)  Prof. Dr. Nicole Basset-Seguin, Paris (France)
Prof. Dr. Alexander Enk, Heidelberg (Germany)  Prof. Dr. Annamari Ranki, Helsinky (Finland)
Prof. Dr. Claudio Feliciani, Rome (Italy)  Prof. Dr. Johannes Ring, Munich (Germany)
Prof. Dr. Claus Garbe, Tuebingen (Germany)  Prof. Dr. Berthold Rzany, Berlin (Germany)
Prof. Dr. Harald Gollnick, Magdeburg (Germany)  Prof. Dr. Rudolf Stadler, Minden (Germany)
Prof. Dr. Gerd Gross, Rostock (Germany)  Prof. Dr. Sonja Stander, Muenster (Germany)
Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia)  Prof. Dr. Wolfram Sterry, Berlin (Germany)
Prof. Dr. Michael Hertl, Marburg (Germany)  Prof. Dr. Eggert Stockfleth, Berlin (Germany)
Prof. Dr. Dimitrios Ioannides, Thessaloniki (Greece)  Prof. Dr. Alain Taieb, Bordeaux (France)
Prof. Dr. Gregor Jemec, Roskilde (Denmark)  Prof. Dr. George-Sorin Tiplica, Bucharest (Romania)
Prof. Dr. Dr. Lajos Kemény, Szeged (Hungary)  Prof. Dr. Nikolai Tsankov, Sofia (Bulgaria)
Dr. Gudula Kirtschig, Amsterdam (Netherlands)  Prof. Dr. Elke Weisshaar, Heidelberg (Germany)
Prof. Dr. Robert Knobler, Vienna (Austria)  Prof. Dr. Sean Whittaker, London (United Kingdom)
Prof. Dr. Annegret Kuhn, Muenster (Germany)  Prof. Dr. Fenella Wojnarowska, Oxford (United Kingdom)
Prof. Dr. Marcus Maurer, Berlin (Germany)  Prof. Dr. Christos Zouboulis, Dessau (Germany)
Prof. Dr. Kai Munte, Rotterdam (Netherlands)  Prof. Dr. Torsten Zuberbier, Berlin (Germany)

Chairman of EDF Guideline Committee:
PD Dr. Alexander Nast, Berlin (Germany)

Expiry date: 07/2017

EDF Guidelines Secretariat to PD Dr. Alexander Nast:
Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte,
Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charite.de
# Conflicts of interests

Pemphigoid. S2 Guidelines for diagnosis and treatment

## The Work Under Consideration for Publication

<table>
<thead>
<tr>
<th>No.</th>
<th>Type of Support</th>
<th>Claudio Feliciani</th>
<th>Pascal Joly</th>
<th>Marcel F. Jonkman</th>
<th>Detlef Zillikens</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grant</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Euroimmun Inc. Miltenyi Inc. Fresenius Inc. Biostest Inc. Dompé Inc.</td>
</tr>
<tr>
<td>2</td>
<td>Consulting fee or honorarium</td>
<td>No</td>
<td>No</td>
<td>Roche, Genetech</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>Support for travel to meetings for the study or other purposes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>Payment for writing or reviewing the manuscript</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>Provision of writing assistance, medicines, equipment, or administrative support</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>Other</td>
<td>No</td>
<td>Roche provides Rituximab for a study which I am conducting</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

## Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th>No.</th>
<th>Type of Support</th>
<th>Claudio Feliciani</th>
<th>Pascal Joly</th>
<th>Marcel F. Jonkman</th>
<th>Detlef Zillikens</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Board membership</td>
<td>No</td>
<td>No</td>
<td>Novartis Abbott Janssen</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>Consultancy</td>
<td>No</td>
<td>No</td>
<td>Glaxo Smith Kline, Stiefel</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>Employment</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>Expert testimony</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>Grants/grants pending</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>Payment for lectures including service on speakers bureaus</td>
<td>No</td>
<td>No</td>
<td>Abbvie</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>Payment for manuscript preparation</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>Patents (planned,</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Euroimmun Inc.</td>
</tr>
<tr>
<td></td>
<td>pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Royalties</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>Payment for development of educational presentations</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>Stock(stock options</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12</td>
<td>Travel(accommodations(meeting expenses unrelated to activities listed)**</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Fresenius Inc. Miltenyi Inc. Abbott Inc. Roche Pharma Inc. UCB Inc.</td>
</tr>
<tr>
<td>13</td>
<td>Other(err on the side of full disclosure)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Other relationships

<table>
<thead>
<tr>
<th></th>
<th>Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No</td>
</tr>
</tbody>
</table>
Conflicts of interests

Pemphigoid. S2 Guidelines for diagnosis and treatment

<table>
<thead>
<tr>
<th>The Work Under Consideration for Publication</th>
<th>Giovanna Zambruno</th>
<th>Dimitrios Ioannides</th>
<th>Cezary Kowalewski</th>
<th>Hana Jedlickova</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Grant</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Clinical trial sponsored by Euroimmun</td>
</tr>
<tr>
<td>2 Consulting fee or honorarium</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3 Support for travel to meetings for the study or other purposes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5 Payment for writing or reviewing the manuscript</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6 Provision of writing assistance, medicines, equipment, or administrative support</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7 Other</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work

<p>| 1 Board membership | No | No | No | No |
| 2 Consultancy      | No | No | No | No |
| 3 Employment       | No | No | No | No |
| 4 Expert testimony | No | No | No | No |
| 5 Grants/grants pending | Dompé S.p.A. research grant “Possible role of IL-8 in pemphigus pathogenesis” (2011-2013) | No | No | No |
| 6 Payment for lectures including service on speakers bureaus | No | No | No | No |
| 7 Payment for manuscript preparation | No | No | No | No |
| 8 Patents (planned, pending or issued) | No | No | No | No |
| 9 Royalties        | No | No | No | No |
| 10 Payment for development of | No | No | No | No |</p>
<table>
<thead>
<tr>
<th></th>
<th>11 Stock/stock options</th>
<th>12 Travel/accommodations/meeting expenses unrelated to activities listed**</th>
<th>13 Other (err on the side of full disclosure)</th>
</tr>
</thead>
<tbody>
<tr>
<td>educational presentations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>13</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other relationships</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>
Conflicts of interests

Pemphigoid. S2 Guidelines for diagnosis and treatment

<table>
<thead>
<tr>
<th>The Work Under Consideration for Publication</th>
<th>Sarolta Karpati</th>
<th>Branka Marinovic</th>
<th>Daniel Mimouni</th>
<th>Soner Uzun</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Grant</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2 Consulting fee or honorarium</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3 Support for travel to meetings for the study or other purposes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5 Payment for writing or reviewing the manuscript</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6 Provision of writing assistance, medicines, equipment, or administrative support</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7 Other</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th>1 Board membership</th>
<th>No</th>
<th>No</th>
<th>No</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Consultancy</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3 Employment</td>
<td>Semmelweis University</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4 Expert testimony</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5 Grants/grants pending</td>
<td>OTKA</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6 Payment for lectures including service on speakers bureaus</td>
<td>Peter Pazmany Catholic University</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7 Payment for manuscript preparation</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>8 Patents (planned, pending or issued)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>9 Royalties</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10 Payment for development of educational presentations</td>
<td>Peter Pazmany Catholic University</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>11 Stock/stock options</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12 Travel/accommodations/meeting expenses unrelated</td>
<td>Support for annual EADV meeting travel/</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Other (err on the side of full disclosure)</td>
<td>accommodation 2013 by EGIS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

### Other relationships

<table>
<thead>
<tr>
<th>Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</th>
<th>No</th>
<th>No</th>
<th>No</th>
<th>No</th>
</tr>
</thead>
</table>

### Conflicts of interests

**Pemphigoid. S2 Guidelines for diagnosis and treatment**

<table>
<thead>
<tr>
<th>The Work Under Consideration for Publication</th>
<th>Savas Yayli</th>
<th>Michael Hertl</th>
<th>Luca Borradori</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Grant</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2 Consulting fee or honorarium</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3 Support for travel to meetings for the study or other purposes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5 Payment for writing or reviewing the manuscript</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6 Provision of writing assistance, medicines, equipment, or administrative support</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7 Other</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

### Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th>1 Board membership</th>
<th>No</th>
<th>Biogen Idec, Roche AG</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Consultancy</td>
<td>No</td>
<td>UCB Pharma</td>
<td>No</td>
</tr>
<tr>
<td>3 Employment</td>
<td>No</td>
<td>No</td>
<td>Government</td>
</tr>
<tr>
<td>4 Expert testimony</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5 Grants/grants pending</td>
<td>No</td>
<td>Fresenius Comp., Biogen Idec, MBL Corp.</td>
<td>No</td>
</tr>
<tr>
<td>6 Payment for lectures including service on speakers bureaus</td>
<td>No</td>
<td>Biogen Idec, MEDAC Comp., MSD Pharma, Biotest Comp., Dermapharm</td>
<td>No</td>
</tr>
<tr>
<td>7 Payment for manuscript preparation</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>8 Patents (planned, pending or issued)</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>9 Royalties</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10 Payment for development of educational</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>presentations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Stock/stock options</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12 Travel/accommodations/meeting expenses unrelated to activities listed**</td>
<td>No</td>
<td>Astellas Pharma, Janssen Cilag</td>
<td>No</td>
</tr>
<tr>
<td>13 Other (err on the side of full disclosure)</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

## Other relationships

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</td>
<td>No</td>
<td>Co-sponsoring of ongoing clinical trial “Efficacy of immunoadsorption in pemphigus” by German Research Council and Fresenius Company</td>
</tr>
</tbody>
</table>
Bullous pemphigoid. S2 Guideline for diagnosis and treatment

On behalf of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV)

C. Feliciani,1 P. Joly,2 M. F. Jonkman,3 G. Zambruno,4 D. Zillikens,5 D. Ioannides,6 C. Kowalewski,7 H. Jedlickova,8 S. Karpati,9 B. Marinovic,10 D. Mimouni,11 S. Uzun,12 S. Yayli,13 M. Hertl14 and L. Borradori15

Departments of Dermatology
1 University of Parma, Parma, Italy;
2 University Hospital, Rouen, France
3 University of Groningen, The Netherlands
4 Istituto Dermopatico dell'Immacolata, IRCCS, Roma, Italy;
5 University of Lübeck, Germany;
6 Aristotle University of Thessaloniki, Greece;
7 Medical University of Warsaw, Poland;
8 Masaryk University, Brno, Czech Republic;
9 Semmelweis University Budapest, Hungary;
10 Zagreb University, Croatia;
11 Tel-Aviv University, Israel;
12 Akdeniz University, Antalya, Turkey;
13 Karadeniz Technical University, Trabzon, Turkey;
14 Philipps-University Marburg, Germany;
15 Inselspital- University Hospital of Bern, Switzerland;

Correspondence
Luca Borradori
luca.borradori@insel.ch

Funding sources
None

Conflict of interest
See attachment
Abstract
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localised or generalised bullous lesions. In up to 20% of affected patients bullae may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarises evidence-based and expert-based recommendations (S2 level).
Introduction
The present guideline for the management of bullous pemphigoid (BP) has been prepared bearing in mind that health care settings and modalities are different amongst European countries, in particular, hospitalisation rules, home-care availability and the possibility of financial reimbursement for different treatments. The aim of the present guideline is to make recommendations for only the most common situations. They are not intended to cover all specific disease variants of BP exhaustively; these are too numerous and too complex to be treated individually. The methodology used to generate this guideline is described in details below (addendum 1).

Initial evaluation of bullous pemphigoid
The initial clinical examination should search for features consistent with the diagnosis of BP and evaluate the patient’s general condition and potential co-morbidities (Table 1).

1.1 Major objectives
- Confirm the diagnosis of BP;
- Search for risk factors and co-morbidities;
- Specify the type of initial damage and its extent (see definitions and outcome measures for BP); 4
- Evaluate the age-dependent prognosis and general condition (Karnofsky performance status scale);
- Consider therapeutic options.

1.2 Professionals involved
The treatment plan for patients with BP should be supervised by a dermatologist familiar with this condition: in most cases, the dermatologist either belongs to a referral centre or is in contact with a referral centre. Other health professionals who should be included in the patient’s management according to the clinical presentation, general conditions and co-morbidities are:
- The consultant dermatologist in general practice;
- The patient's treating physician or, alternatively, a geriatrician, a neurologist, or, very rarely, a paediatrician;
• Specialized nurse (e.g., elderly care medicine, community health service, or home healthcare);
• Dietician, psychologist, physiotherapist, often involved in patient care;
• All other specialists whose expertise is necessary based on the clinical context (neurologists for example).

1.3 Clinical examination

1.3.1 Patient’s history
• The physician should obtain a detailed medical history specifying the date of onset and evolution of signs and symptoms;
• The physician should search for recent drug intake (over a 1 to 6 month period) based on their potential triggering role, such as diuretics.\textsuperscript{5,6}

1.3.2 Physical examination
The physician should search for objective evidence required for diagnosis:
• Classical form: severely pruritic bullous dermatosis, with bullae usually arising from erythematous inflamed skin, symmetric distribution (flexural surfaces of the limbs, medial surface of thighs, abdomen), usually without mucosal involvement and atrophic scarring, and negative Nikolsky's sign;\textsuperscript{1,2,7,8}
• Non-classical/non-bullous forms: pauci-bullous or localised eczema, urticarial lesions dyshidrosiform (acral) lesions, erosions, usually without mucosal involvement (oral in particular), excoriations, prurigo, prurigo nodularis–like lesions;\textsuperscript{7,8}
• The extent of BP should be assessed (see for example BP disease activity index BPDAI or daily blister count).\textsuperscript{4} Finally, the general condition of the patient and the presence of co-morbidities have to be methodically evaluated.

1.4 Laboratory investigations
• Confirm the diagnosis of BP: the diagnosis is based on a combination of criteria encompassing clinical features, compatible light microscopy findings, and positive
specific direct immunofluorescence microscopy (DIF) findings (Table 1). A complete blood count frequently shows eosinophilia.

Proper diagnosis and classification of BP may also require:

- Use of validated clinical criteria based on patient’s characteristics;
- Search for circulating IgG anti-basement membrane autoantibodies by indirect immunofluorescence (IIF) microscopy studies;
- Search for anti-BP180 (also called BPAG2/type XVII collagen) IgG antibodies and anti-BP230 (also called BPAG1-e, epithelial isoform) IgG antibodies by ELISA.

Further technical approaches helpful in confirming the BP diagnosis include (not exhaustive list):

- Analysis of n-serrated pattern on DIF;
- Biochip technique;
- Immunoblotting studies (keratinocyte extracts, recombinant proteins);
- Fluorescence overlay antigen mapping (FOAM);
- Immunelectron microscopy studies of a patient’s skin biopsy specimen.

1.4.1 Histopathology

A skin biopsy preferably with a recent, intact bulla (placed in formalin solution) for routine histopathological analysis. Typical findings consist of subepidermal bullae containing eosinophils and/or neutrophils, associated with a dermal infiltrate of eosinophils and/or neutrophils, or a marginalisation of eosinophils along the dermal-epidermal junction. Nevertheless, in the absence of blistering and in non-bullous forms, histopathological findings may be nonspecific, such as the presence of eosinophilic spongiosis.

1.4.2 Direct immunofluorescence microscopy

DIF studies represent the most critical test: their positivity is essential for the diagnosis of BP.

- A biopsy from perilesional skin (either put into a cryotube for transportation in liquid nitrogen, in Michel's fixative or simply in 0.9% NaCl solution) to demonstrate linear deposits of IgG and/or C3 along the epidermal/dermal-epidermal junction; occasionally IgA and IgE are also found with a similar pattern;
- The analysis of the n-serration pattern of DIF may be helpful and specific in combination with indirect IF studies to differentiate BP from epidermolysis bullosa acquisita;\textsuperscript{15}
- DIF studies on an autologous patient’s skin biopsy specimen cleaved by 1 M NaCl for IgG (IgG deposits after splitting allows differentiation of BP from epidermolysis bullosa acquisita, anti-laminin-332 mucous membrane pemphigoid, and anti-p200 pemphigoid; (note: the location of C3 is not reliable);\textsuperscript{1,2,9,24}
- Immunohistochemistry may be useful for the diagnosis of BP by detecting linear deposits of C3d and C4d along the epidermal basement membrane. Although this approach needs to be validated, it may be helpful in cases in which a second biopsy specimen for DIF studies is not available.\textsuperscript{25}

1.4.3 Immune serological tests
Blood samples (tubes sent to the immunology laboratory or to a reference laboratory) are obtained in order to perform either IIF studies or ELISA. The choice of the approach depends on availability, cost and local expertise.

1.4.3.1 IIF on normal human skin cleaved by the 1 M NaCl technique (or suction-split technique): search for anti-basement membrane IgG auto-antibodies binding to the epidermal side (sometimes epidermal and dermal) of the split skin. By this means, IgG antibodies are found in up to 80\% of cases. Use of non-separated normal human skin or monkey oesophagus is also possible, however associated with lower sensitivity.\textsuperscript{1,2,9,11,18}

1.4.3.2 Search first for anti-BP180 IgG antibodies by ELISA, and, if negative, for anti-BP230 IgG antibodies.\textsuperscript{1,2,12-14,26}

1.4.4 Other tests
Additional tests may be considered according to clinical context and availability:
- Biochip technique. A novel IIF microscopy approach using purified BP180 recombinant proteins and transfected cells expressing BP230 is also available;\textsuperscript{16}
● Immunoblotting studies using different substrates to assess patient’s serum reactivity with BP180 and/or with BP230 or other less frequently targeted antigens;¹²,¹⁴,¹⁷,¹⁸

● FOAM by using either a standard immunofluorescence microscopy or, preferably, laser scanning confocal microscopy.¹⁹,²⁰ This approach verifies the presence of immune deposits (IgG, C3) in the upper part of the lamina lucida (as compared to structural basement membrane antigens used as topographic reference markers);¹⁹,²⁰

● Direct immunelectron microscopy (skin biopsy of peribullous skin) for evidence of immune deposits (IgG, C3) on hemidesmosomes and the adjacent part of the lamina lucida.²¹

2 Therapeutic management (see Table 2)

2.1 Workup and pre-therapy screening

● CBC – complete blood count, ESR and C-reactive protein;
● Creatinine, blood electrolytes;
● Fasting glucose;
● Transaminases, gamma-GT, alkaline phosphatase, bilirubin;
● Albumin;
● Serology for hepatitis B, C and HIV, if immunosuppressive therapy is planned;
● If patient is of childbearing age (very rare), perform pregnancy test prior to treatment;
● If available, testing of thiopurine methyltransferase (TPMT) is optional, when azathioprine is considered as therapeutic option;
● Glucose 6-phosphate dehydrogenase (G6PDH), if dapsone treatment is considered;
● Serum IgA deficiency should be excluded if intravenous immunoglobulins are considered;
● Check for an underlying neoplasm in line with the patient’s age, clinical history and examination as well as for an infection (in particular TBC) if appropriate when immunosuppression needs to be initiated;
● Osteodensitometry (optional, if systemic corticosteroid therapy is planned);
● Ocular examination (optional, ocular tension and cataract, if corticosteroid therapy is planned);
● Local bacteriological sampling if there is any clinical evidence for lesion infection;
• Consider echocardiography before initiation of therapy with either systemic corticosteroids, dapsone, or intravenous immunoglobulins.

2.2 Objectives
Advanced age in affected patients and the potential presence of co-morbidities (neurological, cardiovascular, neoplastic, metabolic and respiratory) make their cases more difficult to manage.1,2,8,27,28

Primary objectives are the control of both the skin eruption and itch as well as to minimize serious side-effects of the treatment. Specifically, the goals of the management are to:
• Treat the skin eruption, reduce itch, and prevent /reduce the risk of recurrence;
• Improve the quality of life of patients;
• Limit the side-effects related to the newly introduced drugs, particularly in the elderly.

2.3 Professionals involved
The initial management, i.e. diagnosis and treatment start, of extended forms of the disease usually requires hospitalisation in a dermatology department if available. Hospitalisation should be continued until clinical control of the bullous eruption is achieved and most of the post-bullous erosions have regressed. In pauci-lesional or localised forms, examinations for diagnostic and clinical monitoring can be performed on an inpatient or outpatient basis depending on the degree of autonomy of the patient.

The management should be coordinated by a dermatologist in contact with treating physicians, specialists and hospital doctors from the centre of reference. Close collaboration between the dermatologist, the treating physician and, if necessary, the nursing staff is therefore fundamental. Exceptionally, the disease can occur in childhood. Affected children should be managed jointly by the specialists, including a paediatrician.

2.4 Therapeutic management
The following recommendations are based on the following level of evidence

(1) Randomised prospective single center or multicenter study. In case that in the latter the intervention is shown effective and not contradicted by other studies, its use is considered validated.
(2) Randomised prospective single centre study (in case of poor methodological quality), retrospective multi-centre study
(3) Case series, retrospective single-centre study
(4) Anecdotal case reports
(5) Expert opinion

2.4.1 Extensive BP
At present there is no general consensus on the definition of extensive BP. While some experts have defined extensive disease as the occurrence of more than 10 new blisters per day, there are patients with a lower new blister count, whose inflammatory lesions cover a large body surface area or areas.

2.4.1.1 Topical treatment
Clobetasol propionate 30 to 40 g/day, initially in two applications, over the entire body including blisters and erosions, but sparing the face (20 g/day if weight <45 kg; level of evidence 1, validated); Current evidence indicates that initial treatment should be first reduced 15 days after disease control (for definitions and outcome measures for BP, see recommendations by an international panel of experts). Earlier reduction of corticosteroid doses is possible but has not been validated in controlled studies.

Definition of disease control: the time point at which new lesions or pruritic symptoms cease to form and established lesions begin to heal.

Tapering schedule and dose adaptation
- Daily treatment in the 1st month; - Treatment every 2 days in the 2nd month;
- Treatment 2 times per week in the 3rd month;
- Treatment once a week starting at in the 4th month.
In patients who do not achieve disease control within 1-3 weeks, increasing dose of topical steroids (up to 40 g/day) is recommended.

Maintenance treatment
Two options are available after 4 months of treatment:
• Continue a maintenance treatment once a week for 9 months (and then stop; level of evidence 1, validated).\textsuperscript{29,30}
  
  o Disadvantage: practical and economic difficulties related to continued nursing for a long period and/or cost of topical high potency steroids.

• Stop treatment (slightly higher risk of relapse but with improved safety when treatment is stopped within 4 months; level of evidence 1, validated).\textsuperscript{30}

Relapse and dose adaptation

• In case of a relapse (see definitions and outcome measures for BP\textsuperscript{4}) during the dose reduction period, the dose is increased to the previous level (level of evidence 1, validated).\textsuperscript{29,30}

• Patients who experience a relapse after treatment withdrawal are treated using the following doses of clobetasol propionate cream (level of evidence 1, validated):\textsuperscript{30}
  
  o 10 g daily for patients with a localized relapse;
  o 20 g daily for patients with mild disease (see below for definition);
  o 30 g daily for patients with extensive relapse.

Additional measures to control disease or for maintenance can be considered and are listed below.

2.4.1.2 Systemic steroid therapy

There is evidence that high-dose systemic steroid therapy, such as prednisone 1 mg/kg/day, is effective in patients with extensive disease (level of evidence 1, validated).\textsuperscript{29,31-33} However, this therapy has been shown to be associated with higher mortality and increased side effects.\textsuperscript{29,31,32} Therefore, the group of experts does not recommend using this dosage in the initial treatment. Doses between 0.5 and 0.75 mg prednisone /kg/day are suggested, despite lack of evidence in extensive disease.\textsuperscript{29,31-33} Prednisone doses lower than 0.5 mg/kg have not been validated and seem to be ineffective.\textsuperscript{34} Systemic treatment may be accompanied by topical therapy with steroids and/or other measures (see below).

Tapering schedule and dose adaptation

• This initial treatment should be first reduced 15 days after disease control. Earlier reduction of corticosteroid doses may be possible.
In patients who do not achieve disease control within 1-3 weeks with 0.5 mg/kg prednisone, the group of experts proposes to increase the dose of prednisone up to 0.75 mg/kg/day, despite the absence of evidence in the literature.

**Maintenance treatment**

Systemic steroids doses should be tapered gradually with the aim to stop treatment or to maintain minimal therapy (0.1 mg/kg/day) within 6 months after initiation of treatment. 30

**Relapse and dose adaptation**

In case of a relapse during the dose reduction period, the dose is increased to the previous level (level of evidence 1, validated). 29

Additional measures to obtain or maintain disease control can be considered and are listed below.

- The choice of an adjuvant or alternative therapy is dependent upon availability, cost issues, practical experience, and the presence of specific contra-indications;
- The use of an immunosuppressive/immunomodulatory therapy with a potentially corticosteroid saving-effect should be considered in the presence of contra-indications to oral corticosteroids and of co-morbidities (such as diabetes, severe osteoporosis, significant cardiovascular problems). Nevertheless, there is no positive evidence supporting their use as first line treatment and they are therefore non-validated; 31-33

The following drugs may be considered (level of evidence between 1 and 3):

- Tetracyclines (oxytetracycline 2 g/day, doxycycline 200 mg/day orally) alone or in combination with nicotinamide (up to 2 g/day orally); 35
- Azathioprine: 1 to 3 mg/kg/day according to TPMT activity; 36-38
- Mycophenolates (mofetil 2 g/day or sodic 1.44 g/day orally); 37,38
- Methotrexate (up to 15 mg once a week orally or subcutaneously or IM); 39
- Dapsone (up to 1.5 mg/kg/day orally); 40
- Chlorambucil (2 to 4 mg/day orally); 41
- Ciclosporine (in selected patients 3-5 mg/kg/day). 42

**2.4.2 Localised / limited and mild BP**

At present, there is no general consensus about the definition of mild BP. While two studies have defined patients with fewer than 10 new blisters per day as having mild disease, 4,29,30 mild
disease can be also defined by the presence of few inflammatory non-bullous or localised lesions involving one body site. In the above mentioned studies around 5 new blisters per day were observed in patients considered as having mild disease.\textsuperscript{29,30}

### 2.4.2.1 Topical treatment

- Patients with localised/limited BP should be preferentially treated initially with topical steroids applied on lesional skin only (clobetasol propionate 10-20 g/day).\textsuperscript{30}
- Patients with mild BP with few but disseminated lesions should be treated with clobetasol propionate 20 g/day in one daily application over the entire body except for the face (10 g/day if weight $<45$ kg; level of evidence 1, validated).\textsuperscript{29,30}

**Tapering schedule and dose adaptation**

Current evidence indicates that initial treatment should be first reduced 15 days after disease control. Earlier reduction of corticosteroid doses may be possible but has not been demonstrated in controlled studies. See above (2.4.1.1. “Extensive bullous pemphigoid”).

- In patients who do not achieve disease control within 1-3 weeks with clobetasol propionate 20 g/day, the recommendation is to increase the dose up to 40 g/day.\textsuperscript{29,30}
- The use of other lower potency steroids in maintenance therapy has not been validated.

### 2.4.2.2 Systemic steroid therapy

There is evidence that 0.5 mg/kg/day prednisone is effective in patients with mild disease (level of evidence 1, validated).\textsuperscript{29} Prednisone doses lower than 0.5 mg/kg have not been validated and seem to be ineffective.\textsuperscript{31-34} This treatment may be accompanied by topical therapy with steroids and/or other measures (see below).

**Maintenance treatment**

Systemic steroid doses should be tapered gradually with the aim to stop treatment or to maintain minimal therapy (0.1 mg/kg/day) within 6 months from initiation of treatment. This recommendation of the expert group needs to be validated (level of evidence 5).

Additional measures to obtain or maintain disease control can be considered and are listed below.
• The choice of an adjuvant or alternative therapy is dependent on its availability, cost aspects, practical experience, and specific contra-indications.
• The use of an immunosuppressive/immunomodulatory therapy with corticosteroid-saving effects should be considered in case of contra-indications to oral corticosteroids and of co-morbidities (such as diabetes, severe osteoporosis, significant cardiovascular disorders). Of note, there is evidence for increased side effects associated with the use of azathioprine.36
• Some evidence supporting the use of tetracyclines and nicotinamide, methotrexate, and dapsone exists, although their use has not been validated in randomized controlled studies of good methodological quality. 31-33 The latter drugs may thus be considered (level of evidence between 1 and 3):
  o Tetracyclines (oxytetracycline 2 g/day, doxycycline 200 mg/day) plus nicotinamide (up to 2 g/day),31-33,35
  o Methotrexate (up to 15mg once a week orally or subcutaneously or IM);39
  o Dapsone (up to 1.5 mg/kg/day orally).40

2.4.3 Treatment-resistant BP
In the cases of those few patients who remain below the controllable level (unresponsive) despite several weeks of intensive therapy with combined topical and systemic steroids, the following therapeutic options might be considered:
• Immunosuppressants: see above (such as methotrexate, azathioprine, mycophenolate mofetil);36-42
• Additional therapies:
  o Intravenous immunoglobulins (level of evidence 3);43
  o Immunoabsorption (level of evidence 4);44,45
  o Anti-CD20 mAb, anti-IgE mAb (level of evidence 4);46-48
  o Cyclophosphamide (level of evidence 3);49
  o Plasma exchange (level of evidence 1).34

2.4.4 Other skin care measures
The use of baths containing antiseptics and/or wheat starch is recommended. In cases of extensive erosive lesions, the latter may be covered by bandages using different types of
dressings, preferably non-adherent, to reduce bacterial super-infection and pain as well as to promote healing.

2.4.5 Other general measures, when required or indicated

- Dietary supplements in malnourished patients.
- Vaccinations. Patients receiving corticosteroids (prednisone at doses of >20 mg per day for >2 weeks) or immunosuppressive therapy should be vaccinated against seasonal influenza, H1N1, and *pneumococcae*. Live attenuated vaccines are contra-indicated.
  - [http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm)

Other prophylactic measures to consider

- Osteoporosis prophylaxis (if expected duration of systemic corticosteroids >3 months);
- TBC prophylaxis/therapy (if necessary);
- *Pneumocystis jirovecii* prophylaxis (optional).

3. Monitoring

BP is a chronic disease which can last for several years in the absence of treatment and has a tendency to relapse.\(^1\text{,}2\text{,}50\text{,}51\)

3.1 Objectives

- To evaluate the efficacy, safety and tolerance of the treatment;
- To gradually reduce and/or adapt treatment, and decide its discontinuation.

3.2 Professionals involved

Specialists and health professionals involved are identical to those listed in the initial evaluation (see § 1.2).

Note: the nursing care required for the application of topical treatments takes usually up to 30 to 45 minutes (encompassing antiseptic baths, bullae count, application of topical steroids, bandaging). It is better to leave small and medium blisters intact as the roof of the blister forms a natural dressing. If the blister is broken remove the fluttering skin.\(^52\)
3.3 Frequency of consultations

Frequency of the follow-up visits and of laboratory tests has to be adapted to:

- The patient's clinical condition;
- The severity and evolution of the disease;
- The treatments used.

Treatment efficacy is essentially monitored and evaluated by clinical examination

- Follow-up frequency: at least weekly until disease control, then
- Monthly for the next 3 months, and then
- Every two months to three times a year until treatment is stopped;
- Monitoring frequency should be adapted to the disease course.

3.4 Clinical examination and laboratory monitoring

The clinical follow-up is identical to that performed during the initial assessment and consists of:

- Examination for skin disease activity (check for blisters, eczematous/urticarial-like lesions, intensity of itch, etc.);
- Check for possible treatment-related side effects and co-morbidities:
  - Degree of skin atrophy, purpura, and skin infections;
- Blood pressure, cardiovascular insufficiency (corticosteroids), respiratory disorders and infections (corticosteroids, immunosuppressants);
- Analysis of WBC, liver and kidney tests (immunosuppressants) and glycaemic value (corticosteroids);
- Immunoserological analyses. Determination of anti-BP180 IgG antibodies by ELISA at days 0, 60, and 150 is useful during treatment because IgG antibody fluctuations measured at these specific endpoints may predict outcome. ⁴¹,⁵⁰,⁵¹ A small decrease -no more than approximately 20%- in anti-BP180 IgG serum levels between days 0 and 60 is a factor associated with disease relapse within the first year of therapy. ⁵⁰ Furthermore, a low or negative anti-BP180 IgG level by ELISA -less than 23 U/mL, i.e. less than two times the upper limit of one of the commercially available kits- at day 150 has a good negative predictive value, since in this case the probability of durable remission is approximately 90%; ⁵¹
• Depending on the drug used, other specific examination may be required and necessary (e.g. for dapsone);
• Osteodensitometry, if indicated (according to patient’s age and conditions).

3.5 Discontinuation of treatment
The optimal duration of treatment has not been defined. Based on clinical experience, we recommend an average treatment duration of 6 to 12 months, except in cases of steroid-resistance or steroid-dependence.

• Discontinuation of treatment is recommended in patients free of symptoms for at least 3 to 6 months under minimal therapy with oral prednisone (0.1 mg/kg/day), or clobetasol propionate (20 g/week), or immunosuppressants;
• Prior to cessation of treatment, the following exams should be performed:
  ○ DIF studies and or ELISA-BP180. In case of either positive DIF studies or ELISA-BP180 (if value > 27 U/mL) there is an increased risk of relapse;
  ○ Be aware and check for potential adrenal insufficiency caused by exogenous steroid use, even after topical application.

3.6 Potential complications
BP can cause permanent complications directly related to either the disease itself or to the treatments used. Affected patients seem to show a significantly increased mortality rate compared to control populations. In this context, proper management of affected patients is necessary and requires specialised personnel.

4. Information for patients
Patients or their families must be informed about the disease, its prognosis, available treatments, possible adverse reactions and therapy-related complications. Furthermore, the need of regular clinical follow-ups to monitor disease activity and to carry out tests to gauge and monitor treatment tolerance must be fully explained. Patients should also be informed of the existence of local or national patients’ associations. The purpose of these associations is to promote knowledge of the disease, to improve patients’ access to information, care, and social services and to interlink them. Thus, a better overall management of the disease can be achieved by
promoting cooperation between patients, patients’ families, patients’ associations and health professionals. Patients’ associations can also help in referring patients to either referral centres or their network of correspondents.

4.1 List of pemphigoid support groups
- Italy: Associazione Nazionale Pemfigo-Pemfigoide Italy (ANPPI): www.pemfigo.it;
- Turkey: http://www.turkdermatoloji.org.tr/
- Netherlands: Netwerk Nederland voor Pemphigus en Pemfigoïd: http://www.pemphigus.nl
- USA: International *Pemphigus* Pemphigoid Foundation: http://www.pemphigus.org/
- Germany: Pemphigus und Pemphigoid Selbštihilfe gruppe e.V.: http://www.pemphigus-pemphigoid-selbštihilfe.de
References


33 Singh S. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. *Indian J Dermatol Venereol Leprol* 2011; 77:456-69.


Bystryn JC. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. *Arch Dermatol* 2008; 144: 946.


Table 1. Diagnostic steps in the evaluation of patients with bullous pemphigoid

Table 2. Bullous pemphigoid: therapeutic ladder
Addendum 1.

Methods
The methodology on which the guidelines is based, is derived from recommendations made by the French Health Agency (HAS) (http://www.has-sante.fr/portail/jcms/c_1340879/fr/protocoles-nationaux-de-diagnostic-et-de-soins-pnds). Two committees - a writing committee and a voting committee - were created. Each committee comprised 8 different experts from different European countries and Israel. None of the experts served in both committees.

In 2012, independent of outside financial support or backing, the voting committee held a 2-day meeting in Frankfurt, the purpose of which was to grade approximately 150 items (from 0 indicating total disagreement to 9 indicating total agreement) relating to key sentences or proposals in the first draft of the guideline compiled by the writing committee. Mean and standard deviation of the 150 items were then calculated. All items graded lower than 7, plus those showing conflicting marks were re-discussed by members of the writing committee and a subsequent second draft was produced. Modified items were then submitted to a second vote by the voting committee to ensure that a mean of higher than 7 had been reached. The draft was emailed to members of the writing committee. Only minor modifications were allowed at this stage. C.F. and L.B. were responsible for collecting and incorporating them into the final text.
Table 1. Diagnostic steps in bullous pemphigoid.

<table>
<thead>
<tr>
<th>CLINICAL EXAMINATION</th>
<th>PHYSICAL EXAMINATION</th>
<th>PATIENT’S ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PATIENT’S HISTORY</strong></td>
<td><strong>CLASSICAL BULLOUS FORM: symmetric distribution of vesicles and bullae over erythematous and non-erythematous skin (flexural surfaces of the limbs, medial surface of thighs, trunk); rare oral mucosal involvement; no atrophic scarring; no Nikolsky's sign</strong></td>
<td>• Extension of BP (by BPDAI or daily blister count) • General condition and co-morbidities • Laboratory examinations and work-up according to patient’s condition and therapy choice</td>
</tr>
<tr>
<td>Date of onset</td>
<td>• Linear (n-serrated) deposits of IgG and/or C3 along the epidermal-dermal junction • Sometimes IgA and IgE with similar pattern</td>
<td></td>
</tr>
<tr>
<td>Evolution of signs and symptoms</td>
<td>• Subepidermal bullae containing eosinophils and/or neutrophils</td>
<td></td>
</tr>
<tr>
<td>Recent drug intake (over 1 to 6 months)</td>
<td>• Dermal infiltrate of eosinophils and/or neutrophils</td>
<td></td>
</tr>
<tr>
<td>Refractory itch of unknown cause in elderly</td>
<td>• Marginalisation of eosinophils along the dermal-epidermal junction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Non-specific findings in atypical forms</td>
<td></td>
</tr>
<tr>
<td><strong>LABORATORY INVESTIGATIONS</strong></td>
<td><strong>DIFFERENTIAL DIAGNOSIS</strong></td>
<td><strong>IMMUNE SEROLOGICAL TESTS</strong></td>
</tr>
<tr>
<td><strong>HISTOPATHOLOGY</strong> (of a recent intact bulla if present)</td>
<td><strong>DIF</strong> (perilesional skin)</td>
<td>• Indirect immunofluorescence microscopy on normal human salt-split-skin (or suction-split): IgG anti-basement membrane antibodies binding to the epidermal side (sometimes epidermal and dermal) of the split</td>
</tr>
<tr>
<td>Subepidermal bullae containing eosinophils and/or neutrophils</td>
<td></td>
<td>• ELISA for antibodies to BP180/BPAG2 and, if negative, for BP230/BPAG1</td>
</tr>
<tr>
<td>Dermal infiltrate of eosinophils and/or neutrophils</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marginalisation of eosinophils along the dermal-epidermal junction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-specific findings in atypical forms</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IMMUNOPATHOLOGICAL TESTS</strong></td>
<td><strong>AUTOANTIGENS</strong></td>
<td><strong>OTHER IMMUNOPATHOLOGICAL TESTS</strong></td>
</tr>
<tr>
<td><strong>IMMUNOBLOTTING</strong></td>
<td><strong>BIOCHIP</strong></td>
<td><strong>FOAM</strong> (intact skin)</td>
</tr>
<tr>
<td>Search for reactivity with BP180 (BPAG2) and/or BP230 (BPAG1). Rarely, additional targeted autoantigens</td>
<td>Indirect immunofluorescence with purified BP180 recombinant protein spotted on slide and transfected cells expressing BP230</td>
<td>Assessment of relative location of detected IgG deposits compared to other proteins within the basement membrane zone</td>
</tr>
</tbody>
</table>
Table 2. Bullous pemphigoid - Therapeutic ladder

<table>
<thead>
<tr>
<th>Localised/limited disease with mild activity</th>
<th>1st choice</th>
<th>2nd choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st choice</td>
<td></td>
<td>Superpotent topical corticosteroids:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- In localised disease: on lesions only (3, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- In mild disease: on whole body except the face (1, validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tetracycline + nicotinamide (2, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dapsone, sulfonamides (3, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topical immunomodulators (e.g. tacrolimus) (4, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral corticosteroids (1, validated for prednisone)</td>
</tr>
<tr>
<td>2nd choice</td>
<td></td>
<td>Dapsone, sulfonamides (3, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topical immunomodulators (e.g. tacrolimus) (4, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral corticosteroids (1, validated for prednisone)</td>
</tr>
<tr>
<td>Generalised disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st choice</td>
<td></td>
<td>Superpotent topical corticosteroids on whole body sparing the face (1, validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral corticosteroids (1, validated for prednisone)</td>
</tr>
<tr>
<td>2nd choice</td>
<td></td>
<td>Combination with or introduction of:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tetracycline + nicotinamide (2, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Azathioprine (1, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mycophenolate (1, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methotrexate (3, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chlorambucil (3, non-validated)</td>
</tr>
<tr>
<td>3rd choice</td>
<td></td>
<td>Anti-CD20 mAb, anti-IgE mAb (4, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intravenous immunoglobulins (3, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immunoadsorption (4, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Plasma exchange (1, non-validated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyclophosphamide (3, non-validated)</td>
</tr>
</tbody>
</table>

Key to evidence-based support: (1) Randomised prospective single center or multicenter study. In case that in the latter the intervention is shown effective and not contradicted by other studies, its use is considered validated; (2) Randomised prospective single centre study (in case of poor methodological quality), retrospective multi-centre study; (3) Case series, retrospective single-center study; (4)Anecdotal case reports; (5) Expert opinion.